Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS Dose Escalation in COVID-19
NCT04659304Phase 1Unknown
- Sponsor
- Enlivex Therapeutics
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label trial of Allocetra in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Enlivex Therapeutics. Primary endpoints: Safety - Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
Allocetra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04659304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659304.